| Market Cap | 1.43B | P/E | - | EPS this Y | 2.70% | Ern Qtrly Grth | - |
| Income | -253.26M | Forward P/E | -7.74 | EPS next Y | 6.30% | 50D Avg Chg | -13.00% |
| Sales | - | PEG | -0.15 | EPS past 5Y | - | 200D Avg Chg | -8.00% |
| Dividend | N/A | Price/Book | 3.12 | EPS next 5Y | 41.70% | 52W High Chg | -27.00% |
| Recommedations | 1.80 | Quick Ratio | 7.63 | Shares Outstanding | 90.98M | 52W Low Chg | 51.00% |
| Insider Own | 3.42% | ROA | -37.13% | Shares Float | 70.90M | Beta | 1.09 |
| Inst Own | 104.51% | ROE | -64.31% | Shares Shorted/Prior | 11.26M/10.92M | Price | 17.81 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 690,312 | Target Price | 43.33 |
| Oper. Margin | - | Earnings Date | Nov 4 | Volume | 331,816 | Change | -0.34% |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
| Canaccord Genuity | Buy | Sep 30, 24 |
| Needham | Buy | Sep 17, 24 |
| JP Morgan | Overweight | Aug 6, 24 |
| Cantor Fitzgerald | Overweight | Aug 6, 24 |
| Chardan Capital | Buy | Aug 6, 24 |
| Needham | Buy | Aug 6, 24 |
| Canaccord Genuity | Buy | Jul 3, 24 |
| Chardan Capital | Buy | Jun 28, 24 |
| Needham | Buy | Jun 28, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Makker Gotham | Director Director | Nov 15 | Sell | 22.5323 | 20,000 | 450,646 | 1,296,497 | 11/16/23 |
| Militello John | See Remarks See Remarks | Oct 20 | Sell | 17.062 | 564 | 9,623 | 8,760 | 10/25/23 |
| Militello John | See Remarks See Remarks | Feb 17 | Sell | 19.06 | 1,076 | 20,509 | 1,782 | 10/20/23 |
| Militello John | See Remarks See Remarks | Feb 17 | Option | 0 | 1,586 | 9,324 | 10/20/23 | |
| Makker Gotham | Director Director | Sep 28 | Sell | 21.09 | 14,989 | 316,118 | 1,316,497 | 10/02/23 |
| Militello John | See Remarks See Remarks | Apr 21 | Sell | 18.65 | 2,342 | 43,678 | 5,636 | 04/25/23 |
| Schwartz Jonathan David | See Remarks See Remarks | Feb 17 | Sell | 19.06 | 3,557 | 67,796 | 94,546 | 02/22/23 |
| Shah Gaurav | CEO CEO | Feb 17 | Sell | 19.06 | 12,194 | 232,418 | 536,885 | 02/22/23 |
| Schwartz Jonathan David | See Remarks See Remarks | Mar 30 | Sell | 16.1 | 135,000 | 2,173,500 | 89,529 | 04/04/22 |
| Shah Gaurav | CEO CEO | Apr 01 | Option | 1.69 | 75,880 | 128,237 | 612,751 | 04/01/21 |
| Patel Kinnari | Chief Operating Offi.. Chief Operating Officer | Mar 26 | Option | 1.45 | 93,962 | 136,245 | 188,939 | 03/26/21 |
| Schwartz Jonathan David | Chief Medical Office.. Chief Medical Officer | Feb 03 | Option | 1.45 | 224,529 | 325,567 | 224,529 | 02/03/21 |